Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: N/A

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for MDP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 28, 2020 08:59 ET
Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide...
Read full article
Feb 18, 2020 18:52 ET
Medexus Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and nine- month periods ended December 31, 2019.  All dollar...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.47
--
--
Price to Sales - TTM
0.86
--
--
Price to Book - most recent quarter
1.78
--
--
Price to Cash Flow per share - TTM
5,710.20
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 15, 20204,900-2,346
Jan 31, 20207,24699
Jan 15, 20207,1473,700
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

Twitter

Search (past week) for $MDP.CA MDP.V

  • No tweets found